minim
extens
risk
factor
infect
differ
period
pretranspl
earli
preengraft
postengraft
period
assess
risk
infect
period
identifi
cation
patient
higher
risk
specifi
c
infect
critic
appropri
manag
infecti
complic
autolog
hsct
import
diffi
cult
element
risk
assess
autolog
hsct
recipi
quantifi
risk
associ
statu
underli
diseas
prior
therapi
exampl
patient
mm
undergo
fi
rst
autolog
hsct
receiv
short
cours
induct
therapi
dexamethason
plu
thalidomid
whose
diseas
control
lower
risk
certain
infect
compar
patient
underli
diseas
receiv
third
fourth
autolog
hsct
set
relaps
multipl
treatment
line
immunodefi
cienci
key
risk
factor
infect
autolog
hsct
recipi
result
interplay
underli
diseas
therapi
may
involv
breakdown
skin
mucou
membran
barrier
qualit
need
addit
chemotherapi
lymphoma
acut
myeloid
leukemia
usual
relat
relaps
underli
diseas
wherea
multipl
myeloma
addit
chemotherapi
usual
part
treatment
strategi
quantit
defect
variou
arm
immun
system
includ
innat
immun
neutropenia
neutrophil
dysfunct
impair
product
immunoglobulin
defect
cellmedi
immun
cmi
autolog
hsct
recipi
defi
cit
variou
arm
immun
system
natur
pathogen
caus
infect
frequent
determin
immunodefi
cienci
predomin
given
time
tabl
pretranspl
variabl
signifi
cantli
impact
risk
major
infect
includ
host
factor
poor
perform
statu
older
age
comorbid
diabet
renal
failur
iron
overload
smoke
high
tumor
burden
addit
risk
pattern
infect
autolog
hsct
strongli
infl
uenc
intens
prior
treatment
underli
diseas
type
treatment
exampl
patient
receiv
purin
analogu
monoclon
antibodi
increas
risk
specifi
c
infect
posttranspl
final
genet
polymorph
gene
link
innat
immun
associ
increas
risk
infect
seri
autolog
hsct
multipl
myeloma
patient
homozyg
wildtyp
mannosebind
lectin
mbl
lower
risk
develop
septicemia
compar
patient
carri
variant
anoth
studi
mbl
defi
cienci
associ
higher
risk
bacteri
infect
mild
moder
sever
sever
mucos
neutropenia
depend
intens
condit
regimen
durat
neutropenia
also
depend
stem
cell
dose
infus
vitro
manipul
stem
cell
product
main
risk
factor
infect
preengraft
period
neutropenia
oral
gastrointestin
mucos
presenc
central
venou
cathet
gener
infect
occur
frequent
longer
period
neutropenia
decreas
rate
bacteremia
observ
util
peripher
blood
instead
marrow
sourc
stem
cell
addit
sever
mucos
associ
increas
risk
infect
indwel
venou
cathet
present
virtual
asct
recipi
earli
period
may
predispos
certain
bloodstream
infect
major
bacteri
infect
neutropenia
caus
gramposit
organ
staphylococci
coagulaseneg
aureu
viridan
streptococci
enterococci
gramneg
bacteria
includ
enterobacteriacea
escherichia
coli
klebsiella
spp
enterobact
spp
nonfer
bacteria
pseudomona
aeruginosa
acinetobact
spp
stenotrophomona
maltophilia
addit
patient
sever
mucos
increas
risk
develop
bloodstream
infect
caus
anaerob
alphahemolyt
streptococci
stenotrophomona
maltophilia
vancomycinresist
enterococci
candida
spp
consider
shift
spectrum
bacteri
infect
occur
time
result
antimicrobi
prophylaxi
therapi
sever
mucotox
drug
widespread
use
intravascular
cathet
late
gramposit
gramneg
organ
equal
distribut
caus
bloodstream
infect
introduct
quinolon
prophylaxi
associ
signifi
cant
reduct
gramneg
infect
cost
increas
infect
caus
gramposit
bacteria
reemerg
bacteremia
resist
gramneg
organ
recent
observ
includ
quinoloneresist
enterobacteriacea
extendedspectrum
clactamas
esbl
produc
bacteria
enterobacteriacea
p
aeruginosa
acinetobact
spp
other
multidrugresist
p
aeruginosa
other
infect
resist
gramposit
organ
also
note
vancomycinresist
enterococci
vre
nosocomi
communityacquir
methicillinresist
aureu
mrsa
seriou
problem
neutropen
patient
leukemia
mark
increas
clostridium
diffi
cile
coliti
retrospect
studi
autolog
hsct
recipi
develop
diarrhea
week
day
hsct
test
c
diffi
cile
toxin
diagnosi
c
diffi
cile
associ
diarrhea
cdad
made
subject
occur
patient
patient
transplant
patient
receiv
mobil
paclitaxel
growth
factor
lower
risk
cdad
compar
patient
mobil
growth
factor
without
cyclophosphamid
receipt
vancomycin
cephalosporin
risk
factor
cdad
great
variabl
exist
within
countri
etiolog
bacteri
infect
suscept
profi
le
intim
knowledg
local
epidemiolog
remain
critic
appli
strategi
prophylaxi
empir
antibiot
therapi
treatment
establish
infect
studi
bacteremia
hsct
recipi
singl
institut
gramposit
gramneg
bacteria
account
bacteremia
respect
rate
bacteremia
decreas
studi
period
particularli
pronounc
gramposit
bacteria
drop
ratio
gramposit
gramneg
organ
prospect
survey
hsct
brazilian
center
patient
develop
bacteremia
earli
posttranspl
period
caus
gramposit
due
gramneg
due
gramposit
gramneg
bacteria
pseudomona
aeruginosa
k
pneumonia
e
coli
frequent
bacteria
among
gramneg
among
gramposit
bacteria
coagulaseneg
staphylococci
aureu
account
major
infect
multidrugresist
mdr
gramneg
bacteria
isol
bacteremia
transplant
receipt
thirdgener
cephalosporin
independ
risk
factor
infect
due
mdr
bacteria
earli
posttranspl
period
gastrointestin
mucos
neutropenia
predispos
occurr
invas
candidiasi
unless
patient
receiv
fl
uconazol
prophylaxi
lead
invas
fungal
infect
period
introduct
fl
uconazol
prophylaxi
incid
candidiasi
decreas
dramat
shift
speci
distribut
fewer
infect
due
c
albican
c
tropicali
increas
infect
caus
c
glabrata
c
krusei
may
illustr
three
epidemiolog
studi
prospect
studi
hsct
autolog
allogen
center
usa
transnet
databas
report
case
invas
candidiasi
c
glabrata
frequent
speci
account
case
invas
candidiasi
diagnos
within
day
autolog
hsct
case
within
month
case
retrospect
studi
involv
center
itali
case
invas
candidiasi
report
among
autolog
hsct
eight
case
caus
c
glabrata
n
c
krusei
n
invas
aspergillosi
occur
typic
patient
profound
neutrophilsmm
prolong
day
neutropenia
durat
neutropenia
autolog
hsct
shorter
incid
invas
aspergillosi
low
howev
patient
concomit
sever
cmi
defi
cienci
risk
group
repres
patient
lymphoma
previous
treat
purin
analogu
heavili
pretreat
myeloma
patient
recent
analyz
cohort
patient
multipl
myeloma
develop
invas
aspergillosi
data
publish
sixtythre
episod
occur
autolog
hsct
median
day
transplant
episod
invas
aspergillosi
occur
preengraft
period
patient
relaps
myeloma
heavili
pretreat
receiv
high
dose
corticosteroid
median
cumul
dose
last
day
mg
patient
prednison
equival
transnet
databas
total
case
invas
aspergillosi
diagnos
autolog
hsct
recipi
forti
case
diagnos
within
day
transplant
italian
retrospect
studi
seven
case
diagnos
autolog
hsct
recipi
except
candidiasi
aspergillosi
invas
fungal
infect
rare
viral
infect
earli
posttranspl
period
limit
reactiv
herp
simplex
viru
hsv
respiratori
viral
infect
infl
uenza
b
parainfl
uenza
respiratori
syncyti
viru
rsv
metapneumoviru
adenoviru
absenc
prophylaxi
acyclovir
valacyclovir
autolog
hsct
recipi
develop
reactiv
hsv
manifest
oral
ulcer
occurr
symptomat
hsv
diseas
particularli
frequent
patient
sever
oral
mucos
although
case
diseas
selflimit
caus
pain
discomfort
may
evolv
pneumonia
result
aspir
oral
secret
viru
although
frequenc
mortal
infect
engraft
much
lower
earli
preengraft
period
infect
signifi
cant
caus
morbid
import
caus
nonrelaps
mortal
retrospect
analysi
autolog
hsct
nonrelaps
death
occur
day
posttranspl
caus
infecti
complic
sepsi
pneumonia
frequent
infect
viral
fungal
diseas
rare
caus
death
risk
infect
postengraft
period
function
dynam
immun
reconstitut
factor
delay
immun
reconstitut
follow
asct
relat
underli
diseas
andor
stem
cell
product
tabl
import
factor
infl
uenc
speed
immun
reconstitut
immun
statu
hsct
need
addit
immunosuppress
treatment
heavili
pretreat
patient
exhibit
sever
immunodefi
cienci
hsct
greater
risk
infecti
complic
likewis
addit
chemotherapi
hsct
greatli
increas
risk
infect
true
patient
mm
receiv
consolid
mainten
hsct
occurr
neutropenia
increas
risk
infect
engraft
studi
receipt
rituximab
independ
risk
factor
delay
onset
neutropenia
receipt
rituximab
pretranspl
also
associ
increas
risk
cmv
reactiv
posttranspl
vitro
manipul
stem
cell
usual
associ
deplet
cell
harvest
result
delay
immun
reconstitut
increas
risk
fungal
viral
protozo
infect
infl
uenc
vitro
manipul
stem
cell
risk
infect
may
illustr
studi
patient
report
high
tcell
content
graft
associ
lower
incid
varicellazost
viru
vzv
reactiv
anoth
studi
autolog
hsct
autoimmun
diseas
cmv
reactiv
observ
vitro
select
howev
studi
patient
lymphoma
mm
breast
cancer
incid
caus
infect
differ
among
patient
receiv
unmanipul
select
peripher
blood
stem
cell
frequenc
etiolog
infect
occur
engraft
assess
autolog
hsct
recipi
nonhodgkin
lymphoma
n
hodgkin
lymphoma
n
mm
n
infect
occur
patient
frequent
infect
vzv
diseas
bronchopneumonia
multivari
analysi
receipt
fl
udarabin
variabl
associ
infect
anoth
studi
patient
breast
cancer
among
patient
prolong
follow
develop
infect
fi
rst
year
posttranspl
upper
respiratori
infect
n
dermatom
vzv
diseas
n
frequent
infect
bacteremia
occur
two
patient
cytomegaloviru
cmv
reactiv
frequent
late
posttranspl
period
retrospect
studi
febril
episod
cmv
seroposit
patient
associ
cmv
reactiv
cmv
infect
sole
caus
fever
prospect
studi
autolog
hsct
recipi
weekli
cmv
antigenemia
perform
engraft
day
posttranspl
forti
cmv
seroposit
patient
present
cmv
reactiv
median
day
transplant
major
patient
n
asymptomat
fever
n
enter
n
clinic
manifest
remain
patient
addit
vzv
cmv
respiratori
viral
infect
frequent
autolog
hsct
recipi
may
contribut
signifi
cant
morbid
especi
patient
lymphopenia
less
frequent
infect
posttranspl
period
includ
hepat
b
c
toxoplasmosi
tuberculosi
pneumocystosi
certain
area
globe
chaga
diseas
infect
repres
import
caus
morbid
autolog
hsct
infect
result
imbal
host
defens
pathogen
risk
vari
accord
phase
hsct
pretranspl
variabl
signifi
cantli
impact
risk
major
infect
includ
host
factor
genet
predisposit
comorbid
condit
tumor
burden
type
durat
intens
prior
chemoor
radiotherapi
hsct
engraft
signifi
cant
risk
factor
includ
neutropenia
mucos
central
venou
cathet
postengraft
period
risk
infect
depend
dynam
immun
reconstitut
follow
hsct
assess
risk
infect
period
identifi
cation
patient
higher
risk
specifi
c
infect
critic
appropri
manag
infecti
complic
autolog
hsct
